Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

主动脉瓣狭窄（AVS）是一个严重的健康问题，影响着150多万美国人和全球数百万人。梅奥诊所的研究人员正在探索使用一种名为阿塔奎特ataciguat的新药来治疗AVS。发表在《循环》杂志上的临床前和临床研究结果表明，阿替奎特有可能显著减缓疾病进展。确定该药物长期有效性和安全性的最后一步是进行三期试验，与行业合作伙伴一起启动这一关键试验的努力很快就会开始。

Sanofi's experimental drug ataciguat has shown promise in reducing the progression of aortic valve stenosis in clinical trials, potentially delaying the need for surgical valve replacement. With ...

The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the ...

An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart ...

Ataciguat, a new drug being studied for aortic valve stenosis, shows promise in slowing disease progression and reducing the ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers at Mayo ...